ID: h-dec9f2e970
Hypothesis
NLRP3 Inhibition (H7): Downstream Inflammatory Reversal
Pharmacological NLRP3 inhibition via MCC950 breaks the lipid-inflammasome feedback loop that perpetuates microglial activation.
EvidencePending (0%)📖 8 cit🗣 1 debates✓ 8 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
Pharmacological NLRP3 inhibition via MCC950 breaks the lipid-inflammasome feedback loop that perpetuates microglial activation. Does not require upstream lipid normalization; directly tests whether established inflammation is reversible. Most clinically actionable surviving hypothesis with tractable medicinal chemistry and established translational pathway.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["NLRP3/NLRP3 (NLRP3 inflammasome)<br/>Primary Target"]
B["Biological Process 1<br/>Mechanistic Step A"]
C["Biological Process 2<br/>Mechanistic Step B"]
D["Output Phenotype<br/>Disease Effect"]
A --> B
B --> C
C --> D
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix8 supports3 contradicts
Supports
Targeting RelA/NLRP3/CCL3 axis mitigates microglia inflammatory response and promotes recovery after spinal cord injury.
Supports
Microglia NLRP3 Inflammasome and Neuroimmune Signaling in Substance Use Disorders.
Supports
Parkin regulates microglial NLRP3 and represses neurodegeneration in Parkinson's disease.
Supports
Galectin-3 activates microglia and promotes neurological impairment via NLRP3/pyroptosis pathway following traumatic brain injury.
Contradicts
Does not prove neuronal AMPK reversibility; addresses downstream symptom rather than upstream cause
Contradicts
If AMPK rescue works but NLRP3 fails, lipid-dependent pathway is upstream and dominant
📖 Linked Papers (5)Export BibTeX ↗
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathology and neurodegeneration.
Journal of neuroinflammation (2025) · PubMed:40122810 ↗
No figures
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathology and neurodegeneration.
Journal of neuroinflammation (2025) · PubMed:40122810 ↗
No figures
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease.
International journal of molecular sciences (2020) · PubMed:33182554 ↗
No figures
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease.
International journal of molecular sciences (2020) · PubMed:33182554 ↗
No figures
Multiple Sclerosis Pathology.
Cold Spring Harbor perspectives in medicine (2018) · PubMed:29358320 ↗
No figures
🏥 Translation
🧬 3D Protein Structure — NLRP3
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for NLRP3/NLRP3 (NLRP3 inflammasome) from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NLRP3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.6%
Volatility
Low
0.0076
Events (7d)
2
Price History
▼19.7%💾 Resource Usage
LLM Tokens
11,236
$0.0337
Total Cost
$0.0337
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF oral NLRP3 inhibitor (MCC950 or derivative) is administered to early-stage Alzheimer's disease patients (MMSE 20-26) at therapeutic dose for 12 weeks THEN cerebrospinal fluid IL-1β concentration wi | Significant reduction in CSF IL-1β (≥30%, p<0.01) and stable or improved MMSE score (+1 to +3 points) with acceptable safety profile. | — no observation — | pending | 0.58 |
| IF MCC950 (10mg/kg, daily IP) is administered to 5xFAD mice starting at 4 months of age for 8 weeks THEN microglial CD68+ IBA1+ activation density in the prefrontal cortex will decrease by ≥35% relati | Significant reduction in microglial activation markers (CD68+ IBA1+ cells/mm²) with effect size Cohen's d ≥ 0.8, along with ≥40% reduction in NLRP3 inflammasome | — no observation — | pending | 0.72 |
🔮 Falsifiable Predictions (2)
pendingconf 72%
IF MCC950 (10mg/kg, daily IP) is administered to 5xFAD mice starting at 4 months of age for 8 weeks THEN microglial CD68+ IBA1+ activation density in the prefrontal cortex will decrease by ≥35% relative to vehicle-treated 5xFAD mice.
Predicted outcome: Significant reduction in microglial activation markers (CD68+ IBA1+ cells/mm²) with effect size Cohen's d ≥ 0.8, along with ≥40% reduction in NLRP3 in
Falsification: No statistically significant reduction in CD68+ IBA1+ density (p>0.05) OR reduction <20% despite confirmed brain MCC950 levels (>100 ng/g tissue) at study endpoint.
pendingconf 58%
IF oral NLRP3 inhibitor (MCC950 or derivative) is administered to early-stage Alzheimer's disease patients (MMSE 20-26) at therapeutic dose for 12 weeks THEN cerebrospinal fluid IL-1β concentration will decrease by ≥30% relative to placebo.
Predicted outcome: Significant reduction in CSF IL-1β (≥30%, p<0.01) and stable or improved MMSE score (+1 to +3 points) with acceptable safety profile.
Falsification: No significant reduction in CSF IL-1β (p>0.05) OR <15% reduction combined with disease progression (MMSE decline ≥3 points) indicating insufficient target engagement for functional benefit.
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.